Investment Summary

Vivo Capital Invests In Synapse Biomedical

On January 1, 2015, growth capital firm Vivo Capital invested in medical products company Synapse Biomedical

Investment Highlights
  • This is Vivo Capital’s 2nd transaction in the Medical Products sector.
  • This is Vivo Capital’s 4th transaction in the United States.
  • This is Vivo Capital’s 1st transaction in Ohio.

Investment Summary
Date 2015-01-01
Target Synapse Biomedical
Sector Medical Products
Investor(s) Vivo Capital
Deal Type Venture

Target

Synapse Biomedical

Oberlin, Ohio, United States
Synapse Biomedical is a medical device company developing neurostimulation products. The company’s products have been approved by the FDA for patients with spinal cord injury and amyotrophic lateral sclerosis. Synapse Biomedical was founded in 2002 and based in Oberlin, Ohio.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Vivo Capital

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1996
PE ASSETS 6.4B USD
Size Mega
Type Sector Focused
DESCRIPTION

Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.

DEAL STATS #
Overall 4 of 18
Sector (Medical Products) 2 of 5
Type (Venture) 3 of 13
State (Ohio) 1 of 1
Country (United States) 4 of 15
Year (2015) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-01-30 Eiger BioPharmaceuticals

Palo Alto, California, United States

Eiger BioPharmaceuticals is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D. Eiger BioPharmaceuticals was incorporated in 2008 and is based in Palo Alto, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-03-05 Tricida

South San Francisco, California, United States

Tricida is a pharmaceutical company focused on developing and commercializing its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Tricida was founded in 2013 and is based in South San Francisco, California.

Buy -
Mergr

Product

Company

Legal